DR-0201, a CD20-directed bispecific antibody, has demonstrated robust B-cell depletion in early clinical studies, showing promise in treating refractory B-cell-mediated autoimmune diseases.

Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid cell engager, from Dren Bio Inc. for $600 million upfront ...

Sanofi is continuing its immunology pipeline push with an agreement to acquire Dren Bio’s bispecific antibody DR-0201 in a ...

Sanofi (NASDAQ:SNY) has struck a major deal to acquire Dren Bios autoimmune disease treatment, DR-0201, reinforcing its ...

Sanofi (SNY) and Dren Bio, a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has ...

Sanofi to pay $600 million upfront payment to buy Dren Bio's bispecific myeloid cell engager, DR-0201: Paris Friday, March 21, 2025, 09:00 Hrs [IST] Sanofi and Dren Bio, Inc., a p ...

The deal is the latest in a series of Sanofi investments in its immunology portfolio. According to Sanfoi, DR-0201 can ...

Sanofi is set to acquire DR-0201 from Dren Bio for up to $1.9 billion, aiming to expand its autoimmune disease pipeline with a promising bispecific antibody.

Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipelineDren Bio deep B-cell ...

Sanofi on Thursday announced an agreement with biopharmaceutical company Dren Bio for the acquisition of its autoimmune disease treatment DR-0201. The French healthcare group will acquire the Dren Bio ...

The sum announced Thursday is an upfront payment for Dren Bio’s drug candidate, DR-0201. The privately held biotech, which is based in Foster City, California, could receive up to $1.3 billion ...

The deal with startup Dren Bio hands Sanofi a so-called myeloid cell engager that would compete with an array of programs aiming to “reset” the immune systems of people with inflammatory conditions.